Cargando…

Is hyperlactatemia a useful screening marker of severe sepsis in hemato-oncologic malignant patients?

Detalles Bibliográficos
Autores principales:	Park, S, Huh, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798109/ http://dx.doi.org/10.1186/2197-425X-3-S1-A300

Ejemplares similares

Catheter-related bloodstream infections in hemato-oncology paediatric patients
por: Giamberardino, HIG, et al.
Publicado: (2015)

Effects of postoperative hyperlactatemia on patients' intensive therapy unit length of stay
por: Thanthulage, S, et al.
Publicado: (2008)

Sepsis-associated hyperlactatemia
por: Garcia-Alvarez, Mercedes, et al.
Publicado: (2014)

Use of CRRT-CVVH in a hemato-oncological ICU in patients treated with defibrotide for veno-occlusive disease in patients after allogeneic hematopoetic stem cell transplantation: single-center experience
por: Navratil, M, et al.
Publicado: (2010)

Hyperlactatemia and low central venous saturation can predict prognosis after cardiac surgery
por: Hajjar, L, et al.
Publicado: (2008)

Systemic symptoms as markers for severity in sepsis
por: Edman-Wallér, J, et al.
Publicado: (2015)

Obesity and inflammatory markers in severe sepsis
por: Simon, P, et al.
Publicado: (2013)

Understanding Hyperlactatemia in Sepsis: Are We There Yet?
por: Nalos, Marek, et al.
Publicado: (2019)

Stem Cells in Hemato-Oncology
por: Damodar, S
Publicado: (2006)

Are phenylcarboxylic acids really markers in severe sepsis?
por: Beloborodova, NV, et al.
Publicado: (2009)

Impact of oncologic pathology (OP) in the evolution of severe sepsis (SS) in the critically ill patients (CIP)
por: Ruiz Moreno, J, et al.
Publicado: (2015)

Procalcitonin as prognostic marker in severe sepsis of abdominal origin
por: Gonzalez-Lisorge, A, et al.
Publicado: (2015)

P-143: Breakthrough – a designated pharmacist in the hemato-oncology department improves both quality and sequence of drug treatment and reduces ADR in Multiple Myeloma patients during Covid-19 pandemic
por: Alabbasi, Areen, et al.
Publicado: (2021)

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
por: Caldwell, Louise, et al.
Publicado: (2022)

Base excess and arterial lactate as early prognostic markers in severe sepsis patients
por: Silva, JM, et al.
Publicado: (2005)

A Study of Pro-Bnp Compared to Procalcitonin in Patient With Severe Sepsis As a Marker of Diagnosis of Sepsis in Critically Ill Patients
por: Elshrief, SR, et al.
Publicado: (2015)

P1569: COVID19 AND ITS IMPACT ON HEMATO-ONCOLOGICAL PATIENTS. DIFFERENCES IN OUTCOMES IN RELATION TO OMICRON CIRCULATION AND VACCINATION STATUS?
por: Addiego, A., et al.
Publicado: (2022)

Lactate as a prognostic marker in patients with severe sepsis or septic shock admitted to the ICU
por: Rocha, LL, et al.
Publicado: (2013)

Evaluation of procalcitonin as a diagnostic and prognostic marker in patients with sepsis, severe sepsis and septic shock associated with ventilator-associated pneumonia
por: Virtzili, S, et al.
Publicado: (2005)

Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients
por: Hricová, Kristýna, et al.
Publicado: (2020)

Understanding Hyperlactatemia in Human Sepsis: Are We Making Progress?
por: De Backer, Daniel, et al.
Publicado: (2019)

PRES in the course of hemato-oncological treatment in children
por: Musioł, Katarzyna, et al.
Publicado: (2017)

Sepsis and neutropenia in hematological malignancies
por: Labiad, Y, et al.
Publicado: (2014)

Outcome in severe sepsis and septic shock patients with hematological malignancies: impact of recent intravenous chemotherapeutic treatment
por: Vandijck, D, et al.
Publicado: (2008)

Endocan can be a predictive marker of severity of sepsis but cannot be a marker of acute respiratory distress syndrome in ICU patients
por: Mizunuma, M, et al.
Publicado: (2015)

Usefulness of sepsis screening tools and education in recognising the burden of sepsis on hospital wards
por: Galtrey, EJ, et al.
Publicado: (2015)

High C-reactive protein and low cholesterol levels are prognostic marker in severe sepsis
por: Memis, D, et al.
Publicado: (2006)

Tissue oxygenation in patients with severe sepsis
por: Oei, A, et al.
Publicado: (2014)

Platelet Septic Transfusion Reactions in Patients With Hemato-Oncological Diseases
por: Razjou, Farhad, et al.
Publicado: (2017)

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Procalcitonin as a marker of bacterial sepsis in immunocompromised patients
por: Gatserelia, Lana, et al.
Publicado: (2012)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

The riddle of hyperlactatemia
por: Gutierrez, Guillermo, et al.
Publicado: (2009)

Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies
por: Cabanillas Stanchi, Karin Melanie, et al.
Publicado: (2019)

Palestinian Children in the Hemato-Oncology Ward of an Israeli Hospital
por: Nehari, Miri, et al.
Publicado: (2008)

Monitoring of the Environment at the Transplant Unit—Hemato-Oncology Clinic
por: Matoušková, Ivanka, et al.
Publicado: (2014)

Hemato-oncology Tourism in Israel: A Retrospective Review
por: Hod, Keren, et al.
Publicado: (2020)

COVID-19 in Omani Children with Hemato-Oncology Diseases
por: Al Yazidi, Laila S, et al.
Publicado: (2020)

Pro-atrial natriuretic peptide in patients with sepsis, severe sepsis and septic shock
por: Prucha, M, et al.
Publicado: (2005)

Relevance of eosinopenia as an early sepsis marker
por: Moura, EB, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7j129uh36tohsk00egj6l2nfkc